“Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed”
$HIMSNo side taken
AI summary · HIMS launched Peptides Plus with five combination therapies, which could draw new customers beyond traditional telehealth and add recurring revenue amid rising peptide demand, but none of the initial treatments is FDA-approved and HIMS says safety, effectiveness and dosing are still uncertain; regulatory and scientific risk could materially threaten its growth plans.
Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.
This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .